Prog Blogs, Orgs & Alumni
Bank Slate
Betsy Devine
birch paper
Democracy for NH
Granite State Progress
Mike Caulfield
Miscellany Blue
Pickup Patriots
Re-BlueNH
Still No Going Back
Susan the Bruce
New Hampshire Labor News
Chaz Proulx: Right Wing Watch
Politicos & Punditry
The Burt Cohen Show
John Gregg
Landrigan
Pindell
Primary Monitor
Scala
Schoenberg
Spiliotes
Campaigns, Et Alia.
NH-Gov
- Maggie Hassan
NH-01
- Andrew Hosmer
- Carol Shea-Porter
- Joanne Dowdell
NH-02
- Ann McLane Kuster
ActBlue Hampshire
NHDP
DCCC
DSCC
DNC
National
Balloon Juice
billmon
Congress Matters
DailyKos
Digby
Hold Fast
Eschaton
FiveThirtyEight
MyDD
Open Left
Senate Guru
Swing State Project
Talking Points Memo
50 State Blog Network
Alabama
Arizona
California
Colorado
Connecticut
Delaware
Florida
Idaho
Illinois
Indiana
Iowa
Louisiana
Maine
Maryland
Massachusetts
Michigan
Minnesota
Missouri
Missouri
Montana
Nebraska
Nevada New Hampshire
New Jersey
New Mexico
New York
North Carolina
North Dakota
Ohio
Oklahoma
Oregon
Rhode Island
Tennessee
Texas
Texas
Utah
Vermont
Virginia
Washington
West Virginia
Wisconsin
I haven't followed this closely - if you have, please correct any misunderstandings on my part.
A federal appeals court has upheld a recent New Hampshire law that blocks the sale of prescription records. The law was challenged by the pharmaceutical industry. By getting these records a drug company could determine (for example) that Dr. Welby was continuing to use an older, perhaps generic, drug rather than their new whiz-bang miracle pill. The company could then educate Welby on all the advantages of their new medication.
There is the potential for good to come of this: new drugs do sometimes offer important new benefits. Doctors are supposed to keep up with those advances, but this could ensure that every doctor prescribing an older drug was informed of the new competitor.
There is also the potential for driving up health care costs, as pharmacy companies target high-pressure tactics on specific doctors to abandon equally effective generics for new, more expensive pills.
The interesting thing about this, to me anyway, is the demonstration of our "fifty laboratories" at work in the U.S.
The challenge to the law claims that it violates "commercial speech" by interfering with the drug companies' efforts to promote their wares. The state argues that these speech rights are trumped by privacy rights. This question has never been litigated before, because New Hampshire's law is the first of its kind.
This happens all the time on legal areas from parental rights to smoking bans: an interest group works with legislators, before or after a bill is passed, to construct model legislation that can be copied elsewhere. That new law is challenged, and if it survives it becomes common across the nation.
(BTW, if the drug companies prevail, I can see no reason why the marketing would not move directly to the patient in a few years. "Elwood, Dr. Welby has been prescribing Aerostuff for your asthma for several years now. Ask him about Pneumopuff - it will provide faster and more long-lasting relief!" the letter will say.)